- Home
- AMIX vs ALZN Comparison
AMIX vs ALZN Comparison
Compare AMIX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- ALZN
- Stock Information
- Founded
- AMIX 2014
- ALZN 2016
- Country
- AMIX United States
- ALZN United States
- Employees
- AMIX N/A
- ALZN N/A
- Industry
- AMIX
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- AMIX
- ALZN Health Care
- Exchange
- AMIX NYSE
- ALZN Nasdaq
- Market Cap
- AMIX 7.3M
- ALZN 6.1M
- IPO Year
- AMIX N/A
- ALZN 2021
- Fundamental
- Price
- AMIX $3.21
- ALZN $1.18
- Analyst Decision
- AMIX
- ALZN Strong Buy
- Analyst Count
- AMIX 0
- ALZN 1
- Target Price
- AMIX N/A
- ALZN $32.00
- AVG Volume (30 Days)
- AMIX 971.1K
- ALZN 145.7K
- Earning Date
- AMIX 02-11-2025
- ALZN 12-12-2024
- Dividend Yield
- AMIX N/A
- ALZN N/A
- EPS Growth
- AMIX N/A
- ALZN N/A
- EPS
- AMIX N/A
- ALZN N/A
- Revenue
- AMIX N/A
- ALZN N/A
- Revenue This Year
- AMIX N/A
- ALZN N/A
- Revenue Next Year
- AMIX N/A
- ALZN N/A
- P/E Ratio
- AMIX N/A
- ALZN N/A
- Revenue Growth
- AMIX N/A
- ALZN N/A
- 52 Week Low
- AMIX $2.55
- ALZN $1.06
- 52 Week High
- AMIX $152.00
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- AMIX 43.28
- ALZN 46.95
- Support Level
- AMIX $2.55
- ALZN $1.13
- Resistance Level
- AMIX $3.23
- ALZN $1.26
- Average True Range (ATR)
- AMIX 0.40
- ALZN 0.07
- MACD
- AMIX 0.19
- ALZN 0.01
- Stochastic Oscillator
- AMIX 41.51
- ALZN 42.03
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.